Breaking News

Yesterday Show Full Stories X To view all stories in expanded form, please subscribe. Get Free Trial Send Info
Hot Stocks	Medtronic announces enrollment in ADAPT-PD trial » 08:36 01/14/21 01/14 08:36 01/14/21 08:36 MDT Medtronic $118.75 / +1.345 (+1.15%) Medtronic announced the… Medtronic announced the first enrollment in ADAPT-PD, its trial evaluating the safety and efficacy of adaptive deep brain stimulation in patients with Parkinson's Disease. Adaptive deep brain stimulation is an investigational feature of the Percept(TM) PC device that could be enabled if approved. The investigational feature used in this study allows for automated adjustment of brain stimulation to provide therapy to manage symptoms of Parkinson's disease based on a patient's clinical state. ShowHide Related Items >><< Company News Street Research Earnings Periodicals On The Fly Events Options MDT Medtronic $118.75 / +1.345 (+1.15%) 01/11/21 Medtronic CEO: We're putting more money into R&D 01/11/21 Medtronic Canada receives expanded indication from Health Canada for Evolut 12/21/20 Medtronic's White sells nearly 11,000 common shares 12/16/20 Medtronic announces FDA approval of navigated interbody, Midas Rex drills MDT Medtronic $118.75 / +1.345 (+1.15%) 01/13/21 Piper Sandler MCIT finalized rule 'important win' for medical technology, says Piper Sandler 01/11/21 Piper Sandler Medtronic updates thoughts on Q3, products, says Piper Sandler 01/07/21 Morgan Stanley Axonics price target raised to $58 from $53 at Morgan Stanley 12/22/20 JPMorgan JPMorgan ups Medtronic target to $130, names a top pick for 2021 MDT Medtronic $118.75 / +1.345 (+1.15%) 11/24/20 Medtronic reports Q2 EPS $1.02, consensus 80c 10/14/20 Medtronic sees long-term annual organic revenue growth of 5% 08/25/20 Medtronic not providing guidance at this time 08/25/20 Medtronic reports Q1 adjusted EPS 62c, consensus 18c MDT Medtronic $118.75 / +1.345 (+1.15%) 10/01/20 DOJ opens ventilator antitrust probe with Medtronic focus, WSJ reports 09/30/20 DoJ opens ventilator antitrust probe with Medtronic focus, WSJ says MDT Medtronic $118.75 / +1.345 (+1.15%) 10/08/20 Tesla upgrade, Citi downgrade among today's top calls on Wall Street 08/25/20 Fly Intel: Wall Street's top stories for Tuesday 08/25/20 Fly Intel: Wall Street's top stories at midday 08/25/20 Fly Intel: Pre-market Movers 00:00 Today 2021 NANS Virtual Meeting MDT Medtronic $118.75 / +1.345 (+1.15%) 10/08/20 Unusually active option classes on open October 8th 08/25/20 Early notable gainers among liquid option names on August 25th 08/25/20 Unusually active option classes on open August 25th

Wednesday
Recommendations	MCIT finalized rule 'important win' for medical technology, says Piper Sandler » 04:58 01/13/21 01/13 04:58 01/13/21 04:58 BSX Boston Scientific $35.32 / -1.12 (-3.07%) , EW Edwards Lifesciences $87.84 / -1.54 (-1.72%) , MASI Masimo $278.15 / -2.07 (-0.74%) , MDT Medtronic $117.41 / -1.005 (-0.85%) , MMSI Merit Medical $55.52 / -0.92 (-1.63%) , STIM Neuronetics $11.69 / -0.36 (-2.99%) , SWAV ShockWave Medical $121.83 / +4.6 (+3.92%) Centers for Medicare and… Centers for Medicare and Medicaid Services yesterday announced that the Medicare Coverage of Innovative Technology proposal announced in August 2020) has been made into a final rule, Piper Sandler analyst Matt O'Brien tells investors in a research note. Under this new rule, medical devices with FDA Breakthrough Device Designation will be eligible for up to four years of national Medicare coverage simultaneously with FDA approval, says the analyst. Additionally, Breakthrough Devices that were approved within the past two calendar years will also be eligible for coverage under this rule, adds the analyst. O'Brien calls the news an "important win" for the medical technology space and believes Boston Scientific (BSX), Edwards Lifesciences (EW), Masimo (MASI), Medtronic (MDT), Merit Medical (MMSI), Neuronetics (STIM) and hockWave Medical (SWAV) stand to benefit. ShowHide Related Items >><< Company News Street Research Earnings Syndicate Periodicals On The Fly Events Options SWAV STIM MMSI MDT MASI EW BSX SWAV ShockWave Medical $121.83 / +4.6 (+3.92%) 12/04/20 ShockWave Medical says CMS creates four new codes for IVL procedures 11/08/20 ShockWave announces unveiling of data from Disrupt PAD III study 10/15/20 ShockWave reports Disrupt CAD III met primary safety, effectiveness endpoints 10/01/20 ShockWave Medical announces updated time for CAD III Investor Webcast Event STIM Neuronetics $11.69 / -0.36 (-2.99%) 01/07/21 Neuronetics announces expansion of sales organization 11/23/20 FDA grants clearance for Neuronetics' TouchStar treatment 11/23/20 Neuronetics receives FDA 510k clearance for NeuroStar Advanced Therapy device 10/13/20 Neuronetics announces publication of data from NeuroStar Outcomes Registry MMSI Merit Medical $55.52 / -0.92 (-1.63%) 08/14/20 Starboard Value boosts Mednax, ACI Worldwide stakes, exits Resideo position 07/29/20 Merit Medical will not issue guidance due to e COVID-19 07/15/20 Merit Medical announces agreement in principle with Department of Justice MDT Medtronic $117.41 / -1.005 (-0.85%) 01/11/21 Medtronic CEO: We're putting more money into R&D 01/11/21 Medtronic Canada receives expanded indication from Health Canada for Evolut 12/21/20 Medtronic's White sells nearly 11,000 common shares 12/16/20 Medtronic announces FDA approval of navigated interbody, Midas Rex drills MASI Masimo $278.15 / -2.07 (-0.74%) 12/10/20 Masimo announces findings from SpHb study 11/30/20 Masimo announces findings from PVi study published 11/02/20 Masimo announces CE marking, limited release of Radius VSM 10/12/20 Masimo announces findings from Masimo ORi study at Anesthesiology 2020 EW Edwards Lifesciences $87.84 / -1.54 (-1.72%) 12/21/20 Edwards Lifesciences: First patient treated in RESTORE clinical trial 12/18/20 Edwards Lifesciences receives expanded approval for SAPIEN 3 TAVI in Canada 12/10/20 Edwards Lifesciences sees FY21 gross profit margin 76%-77% 12/10/20 Edwards Lifesciences sees FY21 CapEx ~$350M BSX Boston Scientific $35.32 / -1.12 (-3.07%) 01/11/21 Boston Scientific announces Lotus Edge recall, sees $225M-$300M of charges 12/14/20 Boston Scientific says stipulation of dismissal filed in Nevro patent case 12/14/20 Nevro to conclude its Boston Scientific lawsuit in DC area 12/01/20 Boston Scientific to sell BTG Specialty Pharmaceuticals business for $800M BSX EW MASI MDT MMSI STIM SWAV BSX Boston Scientific $35.32 / -1.12 (-3.07%) 01/12/21 Piper Sandler Piper says Boston Scientific pullback an opportunity to build positions 12/23/20 Piper Sandler Boston Scientific a name to own at current share levels, says Piper Sandler 12/15/20 Goldman Sachs Boston Scientific downgraded to Buy from Conviction Buy at Goldman Sachs 12/15/20 Goldman Sachs Medtronic upgraded to Neutral from Sell at Goldman Sachs EW Edwards Lifesciences $87.84 / -1.54 (-1.72%) 12/16/20 Citi Edwards Lifesciences downgraded to Neutral from Buy at Citi 12/11/20 Canaccord Edwards Lifesciences price target raised to $94 from $89 at Canaccord 12/11/20 Piper Sandler Edwards Lifesciences price target raised to $98 from $93 at Piper Sandler 12/07/20 Credit Suisse Edwards Lifesciences price target raised to $111 from $97 at Credit Suisse MASI Masimo $278.15 / -2.07 (-0.74%) 11/02/20 Piper Sandler Masimo acquisition brings 'solid opportunity,' says Piper Sandler 10/28/20 Piper Sandler Masimo price target raised to $280 from $250 at Piper Sandler 10/06/20 Piper Sandler Better than expected sensor utilization drove Masimo upside, says Piper Sandler 09/01/20 Baird Masimo initiated with an Outperform at Baird MDT Medtronic $117.41 / -1.005 (-0.85%) 01/11/21 Piper Sandler Medtronic updates thoughts on Q3, products, says Piper Sandler 01/07/21 Morgan Stanley Axonics price target raised to $58 from $53 at Morgan Stanley 12/22/20 JPMorgan JPMorgan ups Medtronic target to $130, names a top pick for 2021 12/15/20 Morgan Stanley Morgan Stanley upgrades Medtronic to Overweight on core improvements, pipeline MMSI Merit Medical $55.52 / -0.92 (-1.63%) 01/05/21 Needham Merit Medical upgraded to Buy from Hold at Needham 01/05/21 Needham Merit Medical upgraded to Buy from Hold at Needham 11/11/20 Wells Fargo Merit Medical price target raised to $58 from $51 at Wells Fargo 11/11/20 Oppenheimer Merit Medical price target raised to $60 from $55 at Oppenheimer STIM Neuronetics $11.69 / -0.36 (-2.99%) 01/12/21 Piper Sandler Neuronetics price target raised to $20 from $9 at Piper Sandler 01/08/21 JMP Securities Neuronetics price target raised to $15 from $10 at JMP Securities 12/07/20 BTIG Neuronetics price target raised to $14 from $10 at BTIG 11/23/20 Piper Sandler Neuronetics price target raised to $9 from $7 at Piper Sandler SWAV ShockWave Medical $121.83 / +4.6 (+3.92%) 01/12/21 Wells Fargo ShockWave Medical price target raised to $134 from $95 at Wells Fargo 12/03/20 Piper Sandler Piper boosts ShockWave Medical target to $96, likes setup into 2021 12/02/20 Oppenheimer Oppenheimer stays at Perform on ShockWave, highlights paper on IVL-induced VFib 12/01/20 BofA ShockWave Medical downgraded to Neutral from Buy at BofA SWAV STIM MMSI MDT MASI EW BSX SWAV ShockWave Medical $121.83 / +4.6 (+3.92%) 11/09/20 ShockWave Medical reports Q3 EPS (38c), consensus (55c) 08/11/20 ShockWave Medical reports Q2 EPS (56c), consensus (62c) STIM Neuronetics $11.69 / -0.36 (-2.99%) 01/12/21 Neuronetics sees FY20 revenue $48.7M-$49.2M, consensus $46.95M 01/12/21 Neuronetics sees Q4 revenue $15M-$15.5M, consensus $13.26M 08/04/20 Neuronetics reports Q2 EPS (41c), consensus (51c) MMSI Merit Medical $55.52 / -0.92 (-1.63%) 10/28/20 Merit Medical sees FY20 EPS $1.52-$1.57, consensus $1.29 10/28/20 Merit Medical reports Q3 EPS 42c, consensus 20c 07/29/20 Merit Medical reports Q2 EPS 31c, consensus 6c MDT Medtronic $117.41 / -1.005 (-0.85%) 11/24/20 Medtronic reports Q2 EPS $1.02, consensus 80c 10/14/20 Medtronic sees long-term annual organic revenue growth of 5% 08/25/20 Medtronic not providing guidance at this time 08/25/20 Medtronic reports Q1 adjusted EPS 62c, consensus 18c MASI Masimo $278.15 / -2.07 (-0.74%) 10/27/20 Masimo sees FY20 non-GAAP EPS $3.46, consensus $3.17 10/27/20 Masimo reports Q3 EPS 80c, consensus 62c 10/06/20 Masimo sees FY20 revenue $1.12B-$1.13B, consensus $1.07B 10/06/20 Masimo sees Q2 revenue $274M-$278M, consensus $243.66M EW Edwards Lifesciences $87.84 / -1.54 (-1.72%) 12/10/20 Edwards Lifesciences sees FY21 adjusted EPS $2.00-$2.20, consensus $2.22 10/21/20 Edwards Lifesciences sees Q4 underlying sales growth 'similar' to Q3 10/21/20 Edwards Lifesciences raises FY20 adj. EPS view to $1.85-$1.95 from $1.75-$1.95 10/21/20 Edwards Lifesciences reports Q3 adjusted EPS 51c, consensus 44c BSX Boston Scientific $35.32 / -1.12 (-3.07%) 01/12/21 Boston Scientific sees FY20 revenue $9.91B, consensus $10.08B 01/12/21 Boston Scientific reports preliminary Q4 revenue $2.71B, consensus $2.86B 10/28/20 Boston Scientific reports Q3 adj. EPS 37c, consensus 25c 10/27/20 Notable companies reporting before tomorrow's open 17 Jun 22 May MDT BSX MDT Medtronic $117.41 / -1.005 (-0.85%) 10/01/20 DOJ opens ventilator antitrust probe with Medtronic focus, WSJ reports 09/30/20 DoJ opens ventilator antitrust probe with Medtronic focus, WSJ says BSX Boston Scientific $35.32 / -1.12 (-3.07%) 07/14/20 Boston Scientific exploring sale of snake venom unit, Bloomberg reports STIM MDT MASI EW BSX STIM Neuronetics $11.69 / -0.36 (-2.99%) 01/12/21 Fly Intel: After-Hours Movers 11/23/20 Fly Intel: After-Hours Movers MDT Medtronic $117.41 / -1.005 (-0.85%) 10/08/20 Tesla upgrade, Citi downgrade among today's top calls on Wall Street 08/25/20 Fly Intel: Wall Street's top stories for Tuesday 08/25/20 Fly Intel: Wall Street's top stories at midday 08/25/20 Fly Intel: Pre-market Movers MASI Masimo $278.15 / -2.07 (-0.74%) 07/28/20 Fly Intel: After-Hours Movers EW Edwards Lifesciences $87.84 / -1.54 (-1.72%) 10/21/20 Fly Intel: After-Hours Movers 07/23/20 Fly Intel: After-Hours Movers 07/13/20 Fly Intel: After-Hours Movers BSX Boston Scientific $35.32 / -1.12 (-3.07%) 01/12/21 Fly Intel: Wall Street's top stories for Tuesday 01/12/21 Fly Intel: Wall Street's top stories at midday 01/12/21 Fly Intel: Pre-market Movers 10/28/20 Fly Intel: Pre-market Movers 01/11/21 2021 ICR Conference 00:00 Today 2021 NANS Virtual Meeting 01/27/21 Edwards Lifesciences - EW 02/03/21 Boston Scientific - BSX STIM MDT EW BSX STIM Neuronetics $11.69 / -0.36 (-2.99%) 09/30/20 Thirteen new option listings and two option delistings on September 30th MDT Medtronic $117.41 / -1.005 (-0.85%) 10/08/20 Unusually active option classes on open October 8th 08/25/20 Early notable gainers among liquid option names on August 25th 08/25/20 Unusually active option classes on open August 25th EW Edwards Lifesciences $87.84 / -1.54 (-1.72%) 11/17/20 Early notable gainers among liquid option names on November 17th BSX Boston Scientific $35.32 / -1.12 (-3.07%) 10/14/20 Boston Scientific put volume heavy and directionally bearish 10/07/20 Boston Scientific put volume heavy and directionally bearish 08/31/20 Boston Scientific put volume heavy and directionally bearish 08/21/20 Boston Scientific call volume above normal and directionally bullish

Monday
Hot Stocks	Medtronic CEO: We're putting more money into R&D » 18:24 01/11/21 01/11 18:24 01/11/21 18:24 MDT Medtronic $118.47 / -1.29 (-1.08%) In an interview on… In an interview on CNBC's Mad Money, Geoff Martha said the use of data will change healthcare. Therapies are improving and becoming more personalized due to advances in technology, he noted. Medtronic is putting more money into R&D and using its balance sheet more than in the past, Martha added. He said the company is "committed" to the dividend and to a double digit return. ShowHide Related Items >><< Company News Street Research Earnings Periodicals On The Fly Events Options MDT Medtronic $118.47 / -1.29 (-1.08%) 01/11/21 Medtronic Canada receives expanded indication from Health Canada for Evolut 12/21/20 Medtronic's White sells nearly 11,000 common shares 12/16/20 Medtronic announces FDA approval of navigated interbody, Midas Rex drills 12/15/20 Medtronic announces results from hundred patients treated with OsteoCool MDT Medtronic $118.47 / -1.29 (-1.08%) 01/11/21 Piper Sandler Medtronic updates thoughts on Q3, products, says Piper Sandler 01/07/21 Morgan Stanley Axonics price target raised to $58 from $53 at Morgan Stanley 12/22/20 JPMorgan JPMorgan ups Medtronic target to $130, names a top pick for 2021 12/15/20 Morgan Stanley Morgan Stanley upgrades Medtronic to Overweight on core improvements, pipeline MDT Medtronic $118.47 / -1.29 (-1.08%) 11/24/20 Medtronic reports Q2 EPS $1.02, consensus 80c 10/14/20 Medtronic sees long-term annual organic revenue growth of 5% 08/25/20 Medtronic not providing guidance at this time 08/25/20 Medtronic reports Q1 adjusted EPS 62c, consensus 18c MDT Medtronic $118.47 / -1.29 (-1.08%) 10/01/20 DOJ opens ventilator antitrust probe with Medtronic focus, WSJ reports 09/30/20 DoJ opens ventilator antitrust probe with Medtronic focus, WSJ says MDT Medtronic $118.47 / -1.29 (-1.08%) 10/08/20 Tesla upgrade, Citi downgrade among today's top calls on Wall Street 08/25/20 Fly Intel: Wall Street's top stories for Tuesday 08/25/20 Fly Intel: Wall Street's top stories at midday 08/25/20 Fly Intel: Pre-market Movers 00:00 Today 2021 NANS Virtual Meeting MDT Medtronic $118.47 / -1.29 (-1.08%) 10/08/20 Unusually active option classes on open October 8th 08/25/20 Early notable gainers among liquid option names on August 25th 08/25/20 Unusually active option classes on open August 25th
Recommendations	Medtronic updates thoughts on Q3, products, says Piper Sandler » 12:58 01/11/21 01/11 12:58 01/11/21 12:58 MDT Medtronic $118.46 / -1.3 (-1.09%) Piper Sandler analyst… Piper Sandler analyst Matt O'Brien made no change to his Overweight rating on Medtronic shares and continues to be "positively inclined" after the company provided updated thoughts on its Q3 at a conference and provided some updates on its pipeline products. O'Brien sees a number of potential growth drivers in the coming years, a strong balance sheet, and a reasonable valuation relative to other diversified names, and noted that the company disclosed that it is developing its own ECAPs closed loop spinal cord stimulation platform which it expects to submit for FDA approval later this year. ShowHide Related Items >><< Company News Street Research Earnings Periodicals On The Fly Events Options MDT Medtronic $118.46 / -1.3 (-1.09%) 01/11/21 Medtronic Canada receives expanded indication from Health Canada for Evolut 12/21/20 Medtronic's White sells nearly 11,000 common shares 12/16/20 Medtronic announces FDA approval of navigated interbody, Midas Rex drills 12/15/20 Medtronic announces results from hundred patients treated with OsteoCool MDT Medtronic $118.46 / -1.3 (-1.09%) 01/07/21 Morgan Stanley Axonics price target raised to $58 from $53 at Morgan Stanley 12/22/20 JPMorgan JPMorgan ups Medtronic target to $130, names a top pick for 2021 12/15/20 Morgan Stanley Morgan Stanley upgrades Medtronic to Overweight on core improvements, pipeline 12/15/20 Goldman Sachs Medtronic upgraded to Neutral from Sell at Goldman Sachs MDT Medtronic $118.46 / -1.3 (-1.09%) 11/24/20 Medtronic reports Q2 EPS $1.02, consensus 80c 10/14/20 Medtronic sees long-term annual organic revenue growth of 5% 08/25/20 Medtronic not providing guidance at this time 08/25/20 Medtronic reports Q1 adjusted EPS 62c, consensus 18c MDT Medtronic $118.46 / -1.3 (-1.09%) 10/01/20 DOJ opens ventilator antitrust probe with Medtronic focus, WSJ reports 09/30/20 DoJ opens ventilator antitrust probe with Medtronic focus, WSJ says MDT Medtronic $118.46 / -1.3 (-1.09%) 10/08/20 Tesla upgrade, Citi downgrade among today's top calls on Wall Street 08/25/20 Fly Intel: Wall Street's top stories for Tuesday 08/25/20 Fly Intel: Wall Street's top stories at midday 08/25/20 Fly Intel: Pre-market Movers 00:00 Today 2021 NANS Virtual Meeting MDT Medtronic $118.46 / -1.3 (-1.09%) 10/08/20 Unusually active option classes on open October 8th 08/25/20 Early notable gainers among liquid option names on August 25th 08/25/20 Unusually active option classes on open August 25th
Hot Stocks	Medtronic Canada receives expanded indication from Health Canada for Evolut » 07:55 01/11/21 01/11 07:55 01/11/21 07:55 MDT Medtronic $119.74 / +1.045 (+0.88%) Medtronic Canada ULC, a… Medtronic Canada ULC, a subsidiary of Medtronic, has received a new expanded indication from Health Canada for its Evolut Transcatheter Aortic Valve Implantation system. Medtronic's TAVI platform is currently the only system licensed for both bicuspid aortic valves as well as all surgical risk categories in Canada. Evolut is now indicated in Canada for severe aortic stenosis patients across all risk categories. With this new indication, over 10,500 people in Canada are potential candidates for this minimally invasive alternative to open-heart surgical valve replacement each year. The expanded indication also allows patients with bicuspid aortic valves at extreme, high and intermediate risk of surgical mortality to also receive the procedure. ShowHide Related Items >><< Company News Street Research Earnings Periodicals On The Fly Events Options MDT Medtronic $119.74 / +1.045 (+0.88%) 12/21/20 Medtronic's White sells nearly 11,000 common shares 12/16/20 Medtronic announces FDA approval of navigated interbody, Midas Rex drills 12/15/20 Medtronic announces results from hundred patients treated with OsteoCool 12/14/20 President of Medtronic's Cardiovascular Portfolio unit Mike Coyle to step down MDT Medtronic $119.74 / +1.045 (+0.88%) 01/07/21 Morgan Stanley Axonics price target raised to $58 from $53 at Morgan Stanley 12/22/20 JPMorgan JPMorgan ups Medtronic target to $130, names a top pick for 2021 12/15/20 Morgan Stanley Morgan Stanley upgrades Medtronic to Overweight on core improvements, pipeline 12/15/20 Goldman Sachs Medtronic upgraded to Neutral from Sell at Goldman Sachs MDT Medtronic $119.74 / +1.045 (+0.88%) 11/24/20 Medtronic reports Q2 EPS $1.02, consensus 80c 10/14/20 Medtronic sees long-term annual organic revenue growth of 5% 08/25/20 Medtronic not providing guidance at this time 08/25/20 Medtronic reports Q1 adjusted EPS 62c, consensus 18c MDT Medtronic $119.74 / +1.045 (+0.88%) 10/01/20 DOJ opens ventilator antitrust probe with Medtronic focus, WSJ reports 09/30/20 DoJ opens ventilator antitrust probe with Medtronic focus, WSJ says MDT Medtronic $119.74 / +1.045 (+0.88%) 10/08/20 Tesla upgrade, Citi downgrade among today's top calls on Wall Street 08/25/20 Fly Intel: Wall Street's top stories for Tuesday 08/25/20 Fly Intel: Wall Street's top stories at midday 08/25/20 Fly Intel: Pre-market Movers 00:00 Today 2021 NANS Virtual Meeting MDT Medtronic $119.74 / +1.045 (+0.88%) 10/08/20 Unusually active option classes on open October 8th 08/25/20 Early notable gainers among liquid option names on August 25th 08/25/20 Unusually active option classes on open August 25th

Over a week ago
Recommendations	Axonics price target raised to $58 from $53 at Morgan Stanley » 08:42 01/07/21 01/07 08:42 01/07/21 08:42 AXNX Axonics $51.56 / +1.14 (+2.26%) , MDT Medtronic $118.83 / +1.95 (+1.67%) Morgan Stanley analyst… Morgan Stanley analyst David Lewis raised the firm's price target on Axonics (AXNX) to $58 from $53 and keeps an Overweight rating on the shares after surveying 54 high-volume physicians who drive about 12% of total U.S. SNM implant volumes. While Medtronic's (MDT) Interstim Micro launch appears to be arresting some of Axonics' share gain momentum, these physicians still expect their share of Axonics' rSNM procedures to grow over the next one to two years, Lewis tells investors. ShowHide Related Items >><< Company News Street Research Earnings Syndicate Periodicals On The Fly Events Options MDT AXNX MDT Medtronic $118.83 / +1.95 (+1.67%) 12/21/20 Medtronic's White sells nearly 11,000 common shares 12/16/20 Medtronic announces FDA approval of navigated interbody, Midas Rex drills 12/15/20 Medtronic announces results from hundred patients treated with OsteoCool 12/14/20 President of Medtronic's Cardiovascular Portfolio unit Mike Coyle to step down AXNX Axonics $51.56 / +1.14 (+2.26%) 11/10/20 Axonics publishes fecal incontinence study results 10/29/20 Axonics submits PMA supplement to FDA to expand MRI labeling 10/20/20 Axonics launches ARTISTRY study for Axonics r-SNM System patients 09/25/20 Medtronic gets affirmation of key sacral neuromodulation patent AXNX MDT AXNX Axonics $51.56 / +1.14 (+2.26%) 12/01/20 BofA ShockWave Medical downgraded to Neutral from Buy at BofA 11/24/20 Piper Sandler Piper says accelerating SNM market an underappreciated positive for Axonics 11/05/20 Truist Axonics price target raised to $58 from $50 at Truist 11/05/20 Wells Fargo Axonics price target raised to $57 from $51 at Wells Fargo MDT Medtronic $118.83 / +1.95 (+1.67%) 12/22/20 JPMorgan JPMorgan ups Medtronic target to $130, names a top pick for 2021 12/15/20 Morgan Stanley Morgan Stanley upgrades Medtronic to Overweight on core improvements, pipeline 12/15/20 Goldman Sachs Medtronic upgraded to Neutral from Sell at Goldman Sachs 12/15/20 Morgan Stanley Medtronic upgraded to Overweight from Equal Weight at Morgan Stanley MDT AXNX MDT Medtronic $118.83 / +1.95 (+1.67%) 11/24/20 Medtronic reports Q2 EPS $1.02, consensus 80c 10/14/20 Medtronic sees long-term annual organic revenue growth of 5% 08/25/20 Medtronic not providing guidance at this time 08/25/20 Medtronic reports Q1 adjusted EPS 62c, consensus 18c AXNX Axonics $51.56 / +1.14 (+2.26%) 11/04/20 Axonics reports Q3 EPS (24c), consensus (50c) 08/06/20 Axonics reports Q2 EPS (54c), consensus (65c) 07/13/20 Axonics reports preliminary Q2 revenue $15.2M, consensus $5.19M 08 May MDT MDT Medtronic $118.83 / +1.95 (+1.67%) 10/01/20 DOJ opens ventilator antitrust probe with Medtronic focus, WSJ reports 09/30/20 DoJ opens ventilator antitrust probe with Medtronic focus, WSJ says 07/07/20 Intersect ENT reviewing Medtronic takeover offer, Bloomberg says 07/07/20 Medtronic makes bid to acquire Intersect ENT, Bloomberg says MDT AXNX MDT Medtronic $118.83 / +1.95 (+1.67%) 10/08/20 Tesla upgrade, Citi downgrade among today's top calls on Wall Street 08/25/20 Fly Intel: Wall Street's top stories for Tuesday 08/25/20 Fly Intel: Wall Street's top stories at midday 08/25/20 Fly Intel: Pre-market Movers AXNX Axonics $51.56 / +1.14 (+2.26%) 11/04/20 Fly Intel: After-Hours Movers 00:00 Today 2021 NANS Virtual Meeting MDT MDT Medtronic $118.83 / +1.95 (+1.67%) 10/08/20 Unusually active option classes on open October 8th 08/25/20 Early notable gainers among liquid option names on August 25th 08/25/20 Unusually active option classes on open August 25th
Recommendations	JPMorgan ups Medtronic target to $130, names a top pick for 2021 » 09:25 12/22/20 12/22 09:25 12/22/20 09:25 MDT Medtronic $114.45 / -0.97 (-0.84%) JPMorgan analyst Robbie… JPMorgan analyst Robbie Marcus raised the firm's price target on Medtronic to $130 from $122 and keeps an Overweight rating on the shares. The analyst also named Medtronic a top large cap pick for 2021. With a new CEO, new operating model, and a "robust" product pipeline, the pieces are in place for Medtronic to deliver a strong 2021, Marcus tells investors in a research note. The analyst sees 2021 as a "significant year for Medtronic as the turnaround story continues to play out." ShowHide Related Items >><< Company News Street Research Earnings Periodicals On The Fly Options MDT Medtronic $114.45 / -0.97 (-0.84%) 12/21/20 Medtronic's White sells nearly 11,000 common shares 12/16/20 Medtronic announces FDA approval of navigated interbody, Midas Rex drills 12/15/20 Medtronic announces results from hundred patients treated with OsteoCool 12/14/20 President of Medtronic's Cardiovascular Portfolio unit Mike Coyle to step down MDT Medtronic $114.45 / -0.97 (-0.84%) 12/15/20 Morgan Stanley Morgan Stanley upgrades Medtronic to Overweight on core improvements, pipeline 12/15/20 Goldman Sachs Medtronic upgraded to Neutral from Sell at Goldman Sachs 12/15/20 Morgan Stanley Medtronic upgraded to Overweight from Equal Weight at Morgan Stanley 12/14/20 Piper Sandler Resignation of Medtronic President of Cardiovascular a surprise, says Piper MDT Medtronic $114.45 / -0.97 (-0.84%) 11/24/20 Medtronic reports Q2 EPS $1.02, consensus 80c 10/14/20 Medtronic sees long-term annual organic revenue growth of 5% 08/25/20 Medtronic not providing guidance at this time 08/25/20 Medtronic reports Q1 adjusted EPS 62c, consensus 18c MDT Medtronic $114.45 / -0.97 (-0.84%) 10/01/20 DOJ opens ventilator antitrust probe with Medtronic focus, WSJ reports 09/30/20 DoJ opens ventilator antitrust probe with Medtronic focus, WSJ says 07/07/20 Intersect ENT reviewing Medtronic takeover offer, Bloomberg says 07/07/20 Medtronic makes bid to acquire Intersect ENT, Bloomberg says MDT Medtronic $114.45 / -0.97 (-0.84%) 10/08/20 Tesla upgrade, Citi downgrade among today's top calls on Wall Street 08/25/20 Fly Intel: Wall Street's top stories for Tuesday 08/25/20 Fly Intel: Wall Street's top stories at midday 08/25/20 Fly Intel: Pre-market Movers MDT Medtronic $114.45 / -0.97 (-0.84%) 10/08/20 Unusually active option classes on open October 8th 08/25/20 Early notable gainers among liquid option names on August 25th 08/25/20 Unusually active option classes on open August 25th 06/30/20 Largest borrow rate increases among liquid names
Hot Stocks	Medtronic's White sells nearly 11,000 common shares » 17:10 12/21/20 12/21 17:10 12/21/20 17:10 MDT Medtronic $114.45 / -0.97 (-0.84%) In a regulatory filing,… In a regulatory filing, Medtronic EVP and President, Medical Surgical, Robert John White disclosed the sale of 10,930 ordinary shares of the company on December 18 at a price of $115.46 per share. ShowHide Related Items >><< Company News Street Research Earnings Periodicals On The Fly Options MDT Medtronic $114.45 / -0.97 (-0.84%) 12/16/20 Medtronic announces FDA approval of navigated interbody, Midas Rex drills 12/15/20 Medtronic announces results from hundred patients treated with OsteoCool 12/14/20 President of Medtronic's Cardiovascular Portfolio unit Mike Coyle to step down 12/08/20 Medtronic launches pediatric, neonatal acute dialysis machine in U.S. MDT Medtronic $114.45 / -0.97 (-0.84%) 12/15/20 Morgan Stanley Morgan Stanley upgrades Medtronic to Overweight on core improvements, pipeline 12/15/20 Goldman Sachs Medtronic upgraded to Neutral from Sell at Goldman Sachs 12/15/20 Morgan Stanley Medtronic upgraded to Overweight from Equal Weight at Morgan Stanley 12/14/20 Piper Sandler Resignation of Medtronic President of Cardiovascular a surprise, says Piper MDT Medtronic $114.45 / -0.97 (-0.84%) 11/24/20 Medtronic reports Q2 EPS $1.02, consensus 80c 10/14/20 Medtronic sees long-term annual organic revenue growth of 5% 08/25/20 Medtronic not providing guidance at this time 08/25/20 Medtronic reports Q1 adjusted EPS 62c, consensus 18c MDT Medtronic $114.45 / -0.97 (-0.84%) 10/01/20 DOJ opens ventilator antitrust probe with Medtronic focus, WSJ reports 09/30/20 DoJ opens ventilator antitrust probe with Medtronic focus, WSJ says 07/07/20 Intersect ENT reviewing Medtronic takeover offer, Bloomberg says 07/07/20 Medtronic makes bid to acquire Intersect ENT, Bloomberg says MDT Medtronic $114.45 / -0.97 (-0.84%) 10/08/20 Tesla upgrade, Citi downgrade among today's top calls on Wall Street 08/25/20 Fly Intel: Wall Street's top stories for Tuesday 08/25/20 Fly Intel: Wall Street's top stories at midday 08/25/20 Fly Intel: Pre-market Movers MDT Medtronic $114.45 / -0.97 (-0.84%) 10/08/20 Unusually active option classes on open October 8th 08/25/20 Early notable gainers among liquid option names on August 25th 08/25/20 Unusually active option classes on open August 25th 06/30/20 Largest borrow rate increases among liquid names
Hot Stocks	Medtronic announces FDA approval of navigated interbody, Midas Rex drills » 08:03 12/16/20 12/16 08:03 12/16/20 08:03 MDT Medtronic $114.84 / +2.855 (+2.55%) Medtronic announced that… Medtronic announced that the U.S. FDA has cleared the use of navigated interbody and Midas Rex high speed drills with the Mazor Robotic Guidance System earlier than originally anticipated. The Mazor platform now provides surgeons with unprecedented procedural integration by seamlessly combining the power of Midas Rex drills with the market leading visibility and navigation from the StealthStation software. The solution delivers the confidence of access and interbody navigation and predictability of planning, along with the precision of robotic technology that surgeons expect from the Mazor Robotic Guidance System and the exclusive Medtronic robotics portfolio. ShowHide Related Items >><< Company News Street Research Earnings Periodicals On The Fly Events Options MDT Medtronic $114.84 / +2.855 (+2.55%) 12/15/20 Medtronic announces results from hundred patients treated with OsteoCool 12/14/20 President of Medtronic's Cardiovascular Portfolio unit Mike Coyle to step down 12/08/20 Medtronic launches pediatric, neonatal acute dialysis machine in U.S. 11/24/20 Medtronic sees returning to normal organic revenue growth by Q4 MDT Medtronic $114.84 / +2.855 (+2.55%) 12/15/20 Morgan Stanley Morgan Stanley upgrades Medtronic to Overweight on core improvements, pipeline 12/15/20 Goldman Sachs Medtronic upgraded to Neutral from Sell at Goldman Sachs 12/15/20 Morgan Stanley Medtronic upgraded to Overweight from Equal Weight at Morgan Stanley 12/14/20 Piper Sandler Resignation of Medtronic President of Cardiovascular a surprise, says Piper MDT Medtronic $114.84 / +2.855 (+2.55%) 11/24/20 Medtronic reports Q2 EPS $1.02, consensus 80c 10/14/20 Medtronic sees long-term annual organic revenue growth of 5% 08/25/20 Medtronic not providing guidance at this time 08/25/20 Medtronic reports Q1 adjusted EPS 62c, consensus 18c MDT Medtronic $114.84 / +2.855 (+2.55%) 10/01/20 DOJ opens ventilator antitrust probe with Medtronic focus, WSJ reports 09/30/20 DoJ opens ventilator antitrust probe with Medtronic focus, WSJ says 07/07/20 Intersect ENT reviewing Medtronic takeover offer, Bloomberg says 07/07/20 Medtronic makes bid to acquire Intersect ENT, Bloomberg says MDT Medtronic $114.84 / +2.855 (+2.55%) 10/08/20 Tesla upgrade, Citi downgrade among today's top calls on Wall Street 08/25/20 Fly Intel: Wall Street's top stories for Tuesday 08/25/20 Fly Intel: Wall Street's top stories at midday 08/25/20 Fly Intel: Pre-market Movers 12/15/20 Enforcement, Litigation & Compliance Conference MDT Medtronic $114.84 / +2.855 (+2.55%) 10/08/20 Unusually active option classes on open October 8th 08/25/20 Early notable gainers among liquid option names on August 25th 08/25/20 Unusually active option classes on open August 25th 06/30/20 Largest borrow rate increases among liquid names
Conference/Events	Food & Drug Law Institute to hold a virtual conference » 04:55 12/16/20 12/16 04:55 12/16/20 04:55 BDX Becton Dickinson $244.15 / +3.8 (+1.58%) , DNA Bought by RHHBY $0.00 / + (+0.00%) , EXPO Exponent $87.74 / +1.61 (+1.87%) , LLY Eli Lilly $167.46 / +9.5 (+6.01%) , MDT Medtronic $114.84 / +2.855 (+2.55%) , PFE Pfizer $38.72 / -0.51 (-1.30%) , ZGNX Zogenix $21.01 / -0.13 (-0.61%) Enforcement, Litigation… Enforcement, Litigation & Compliance Conference will be held on December 15-16. Webcast Link ShowHide Related Items >><< Company News Street Research Earnings Syndicate Periodicals On The Fly Events Options ZGNX PFE MDT LLY BDX ZGNX Zogenix $21.01 / -0.13 (-0.61%) 12/03/20 Zogenix and Tevard Biosciences to develop therapies for Dravet syndrome 10/29/20 Zogenix announces date change for Q3 results 10/16/20 Zogenix receives positive CHMP opinion for FINTEPLA oral solution 10/15/20 Zogenix presents new Fintepla data in Dravet syndrome showing seizure reduction PFE Pfizer $38.72 / -0.51 (-1.30%) 12/15/20 Pfizer CEO sees vaccine from plants to any U.S. point of use within two days 12/14/20 Pfizer, BioNTech announce additional data from Phase 1/2 trial of BNT162b2 12/13/20 Fly Intel: Top five weekend stock stories 12/13/20 CDC Committee recommends Pfizer, BioNTech COVID vaccine for '16 years and older' MDT Medtronic $114.84 / +2.855 (+2.55%) 12/15/20 Medtronic announces results from hundred patients treated with OsteoCool 12/14/20 President of Medtronic's Cardiovascular Portfolio unit Mike Coyle to step down 12/08/20 Medtronic launches pediatric, neonatal acute dialysis machine in U.S. 11/24/20 Medtronic sees returning to normal organic revenue growth by Q4 LLY Eli Lilly $167.46 / +9.5 (+6.01%) 12/15/20 Eli Lilly to acquire Prevail Therapeutics for up to $26.50 per share in cash 12/14/20 Eli Lilly increases quarterly dividend 15% 12/14/20 Eli Lilly announces opening of patient enrollment for New IDEAS study 12/11/20 Lilly, Incyte say NEJM publishes results from Adaptive COVID-19 treatment trial BDX Becton Dickinson $244.15 / +3.8 (+1.58%) 12/15/20 Mettler-Toledo CEO Olivier Filliol to step down, Patrick Kaltenbach to succeed 12/09/20 Becton Dickinson announces publication of BD Libertas Wearable Injector trial 12/02/20 Becton Dickinson to invest $1.2B to expand capacity for PFS, ADDS 12/02/20 Becton Dickinson to invest $1.2B in pre-fillable syringe manufacturing capacity BDX DNA EXPO LLY MDT PFE ZGNX BDX Becton Dickinson $244.15 / +3.8 (+1.58%) 12/15/20 Fly Intel: Top five analyst downgrades 12/15/20 Fly Intel: Top five analyst upgrades 12/15/20 Morgan Stanley Morgan Stanley upgrades 'self help story in disguise' Becton Dickinson 12/15/20 Wells Fargo Wells Fargo says Buy Inari Medical, Sell NuVasive in MedTech ratings shake-up DNA Bought by RHHBY $0.00 / + (+0.00%) EXPO Exponent $87.74 / +1.61 (+1.87%) 05/13/20 Sidoti Exponent upgraded to Buy from Neutral at Sidoti 04/09/20 Sidoti Exponent downgraded to Neutral from Buy at Sidoti 03/19/20 Sidoti Exponent upgraded to Buy from Neutral at Sidoti 03/19/20 Sidoti Exponent upgraded to Buy from Neutral at Sidoti LLY Eli Lilly $167.46 / +9.5 (+6.01%) 12/15/20 Piper Sandler Prevail Therapeutics downgraded to Neutral from Overweight at Piper Sandler 12/10/20 Wolfe Research Eli Lilly upgraded to Outperform from Peer Perform at Wolfe Research 12/10/20 Wolfe Research Eli Lilly upgraded to Outperform from Peer Perform at Wolfe Research 12/04/20 JPMorgan Eli Lilly best positioned growth story in space, says JPMorgan MDT Medtronic $114.84 / +2.855 (+2.55%) 12/15/20 Morgan Stanley Morgan Stanley upgrades Medtronic to Overweight on core improvements, pipeline 12/15/20 Goldman Sachs Medtronic upgraded to Neutral from Sell at Goldman Sachs 12/15/20 Morgan Stanley Medtronic upgraded to Overweight from Equal Weight at Morgan Stanley 12/14/20 Piper Sandler Resignation of Medtronic President of Cardiovascular a surprise, says Piper PFE Pfizer $38.72 / -0.51 (-1.30%) 12/15/20 Jefferies Jefferies starts Maravai at Buy, says 'more than just a COVID vaccine play' 12/14/20 Jefferies Novavax initiated with a Buy at Jefferies 12/14/20 Citi Arcturus Therapeutics price target raised to $133 from $62 at Citi 12/08/20 Roth Capital Turning Point Therapeutics price target raised to $140 from $133 at Roth Capital ZGNX Zogenix $21.01 / -0.13 (-0.61%) 12/04/20 Mizuho Zogenix collaboration step in right direction, says Mizuho 08/24/20 Raymond James Zogenix initiated with a Market Perform at Raymond James 07/15/20 Stifel Physician survey suggests Zogenix shares undervalued, says Stifel 06/29/20 Mizuho Zogenix price target lowered to $55 from $64 at Mizuho ZGNX PFE MDT LLY EXPO BDX ZGNX Zogenix $21.01 / -0.13 (-0.61%) 11/09/20 Zogenix reports Q3 EPS ($1.08), consensus (98c) 08/05/20 Zogenix reports Q2 EPS (96c), consensus ($1.00) PFE Pfizer $38.72 / -0.51 (-1.30%) 10/27/20 Pfizer sees FY20 Upjohn revenue $8B-$8.5B, adjusted EBITDA $3.8B-$4.2B 10/27/20 Pfizer sees FY20 adjusted EPS for New Pfizer $2.28-$2.38, revenue $40.8B-$42.4B 10/27/20 Pfizer narrows FY20 adjusted EPS view to $2.88-$2.93 from $2.85-$2.95 10/27/20 Pfizer reports Q3 adjusted EPS 72c, consensus 71c MDT Medtronic $114.84 / +2.855 (+2.55%) 11/24/20 Medtronic reports Q2 EPS $1.02, consensus 80c 10/14/20 Medtronic sees long-term annual organic revenue growth of 5% 08/25/20 Medtronic not providing guidance at this time 08/25/20 Medtronic reports Q1 adjusted EPS 62c, consensus 18c LLY Eli Lilly $167.46 / +9.5 (+6.01%) 12/15/20 Eli Lilly sees FY21 EPS $7.75-$8.40, consensus $8.07 12/15/20 Eli Lilly raises FY20 EPS view to $7.45-$7.65 from $7.20-$7.40, consensus $7.32 12/02/20 Eli Lilly says updated purchase of LY-CoV555 to boost FY20 EPS view by 25c 10/27/20 Eli Lilly backs FY20 adj. EPS view $7.20-$7.40, consensus $7.28 EXPO Exponent $87.74 / +1.61 (+1.87%) 10/29/20 Exponent sees Q4 revenue down 12%-15% amid COVID headwinds 10/29/20 Exponent reports Q3 EPS 34c, consensus 31c 10/29/20 Exponent reports Q3 EPS 34c, consensus 31c 07/30/20 Exponent reports Q2 EPS 31, consensus 25c BDX Becton Dickinson $244.15 / +3.8 (+1.58%) 11/05/20 Becton Dickinson sees FY21 adj. EPS $12.40-$12.60, consensus $12.53 11/05/20 Becton Dickinson reports Q4 adj. EPS $2.79, consensus $2.52 11/04/20 Notable companies reporting before tomorrow's open 21 May 04 Mar ZGNX PFE MDT LLY BDX ZGNX Zogenix $21.01 / -0.13 (-0.61%) 06/25/20 FDA approves Zogenix's Fintepla as therapy for Dravet Syndrome, Bloomberg says PFE Pfizer $38.72 / -0.51 (-1.30%) 12/15/20 Pfizer, U.S. government negotiating deal for more COVID vaccine doses, NYT says 12/15/20 Pfizer CEO hasn't gotten Covid vaccine yet, CNBC reports 12/11/20 FDA tells Bloomberg report of Hahn firing threat 'untrue' account of call 12/11/20 FDA head ordered to approve vaccine today or quit, Washington Post reports MDT Medtronic $114.84 / +2.855 (+2.55%) 10/01/20 DOJ opens ventilator antitrust probe with Medtronic focus, WSJ reports 09/30/20 DoJ opens ventilator antitrust probe with Medtronic focus, WSJ says 07/07/20 Intersect ENT reviewing Medtronic takeover offer, Bloomberg says 07/07/20 Medtronic makes bid to acquire Intersect ENT, Bloomberg says LLY Eli Lilly $167.46 / +9.5 (+6.01%) 11/23/20 EU seeks easier access to generic medicines, Reuters says 11/20/20 Trump to release new rules aimed at lowering drug prices, WSJ reports 10/26/20 Eli Lilly: Gov't trial of COVID-19 treatment in hospital to end, Bloomberg says 10/21/20 Eli Lilly hires advisor to review plant producing C-19 treatment, CNBC reports BDX Becton Dickinson $244.15 / +3.8 (+1.58%) 09/14/20 Becton Dickinson investigating false-positive COVID-19 test results, WSJ reports 09/09/20 Report says U.S. may need 193M coronavirus tests per month, STAT reports ZGNX PFE MDT LLY BDX ZGNX Zogenix $21.01 / -0.13 (-0.61%) 11/09/20 Fly Intel: After-Hours Movers 10/15/20 Fly Intel: After-Hours Movers 09/22/20 Fly Intel: After-Hours Movers 06/26/20 Fly Intel: Pre-market Movers PFE Pfizer $38.72 / -0.51 (-1.30%) 12/11/20 Fly Intel: Wall Street's top stories for Friday 12/11/20 Fly Intel: Wall Street's top stories at midday 12/09/20 Fly Intel: Wall Street's top stories for Wednesday MDT Medtronic $114.84 / +2.855 (+2.55%) 10/08/20 Tesla upgrade, Citi downgrade among today's top calls on Wall Street 08/25/20 Fly Intel: Wall Street's top stories for Tuesday 08/25/20 Fly Intel: Wall Street's top stories at midday 08/25/20 Fly Intel: Pre-market Movers LLY Eli Lilly $167.46 / +9.5 (+6.01%) 12/15/20 Fly Intel: Wall Street's top stories for Tuesday 12/15/20 Fly Intel: Wall Street's top stories at midday 12/15/20 Fly Intel: Pre-market Movers 11/21/20 Week in review: How Trump's policies moved stocks BDX Becton Dickinson $244.15 / +3.8 (+1.58%) 08/27/20 Fly Intel: Wall Street's top stories at midday 08/27/20 Abbott Labs jumps after securing FDA approval for $5 COVID-19 test 08/06/20 Fly Intel: Pre-market Movers 07/06/20 Fly Intel: Wall Street's top stories for Monday 12/15/20 Enforcement, Litigation & Compliance Conference 01/29/21 Eli Lilly - LLY 12/16/20 Cardiovascular and Renal Drugs Advisory Committee Meeting 01/24/21 PDUFA Date for Xalkori (Crizotinib) - January 2021 ZGNX PFE MDT LLY ZGNX Zogenix $21.01 / -0.13 (-0.61%) 11/19/20 Unusual call flow in option market yesterday 11/18/20 Upside call Seller in Zogenix 06/26/20 Unusually active option classes on open June 26th 06/23/20 Zogenix call volume above normal and directionally bullish PFE Pfizer $38.72 / -0.51 (-1.30%) 12/15/20 Notable open interest changes for December 15th 12/14/20 Unusually active option classes on open December 14th 12/11/20 Unusually active option classes on open December 11th 12/11/20 Notable open interest changes for December 11th MDT Medtronic $114.84 / +2.855 (+2.55%) 10/08/20 Unusually active option classes on open October 8th 08/25/20 Early notable gainers among liquid option names on August 25th 08/25/20 Unusually active option classes on open August 25th 06/30/20 Largest borrow rate increases among liquid names LLY Eli Lilly $167.46 / +9.5 (+6.01%) 12/09/20 Early notable gainers among liquid option names on December 9th 12/09/20 Unusually active option classes on open December 9th 10/27/20 Unusually active option classes on open October 27th 10/12/20 Unusually active option classes on open October 12th

On The Fly

News and insights, exclusive to thefly.com

09:52	Fly Intel: Top five analyst initiations»
09:52	Fly Intel: Top five analyst downgrades»
09:52	Fly Intel: Top five analyst upgrades»
06:39	Citi cuts Spotify to Sell with no benefit seen on podcast investments»
20:25	Notable companies reporting before tomorrow's open»

View all On The Fly Stories »

Upcoming
Events (10)

	Private Data Center Virtual Symposium
BSX ...	2021 NANS Virtual Meeting
	Utility CEO Retreat 1:1 Virtual Conference
	China Renewable Energy Virtual Corporate Days Conference
NOVA	Sustainability: Solar
	Greater China Virtual Conference & Virtual Tours 2021
	ASCO-GI: Gastrointestinal Cancers Virtual Symposium
	Greater China Healthcare Virtual Corporate Day
GPX ...	23rd Annual Virtual Growth Conference
	European Utilities & Infrastructure Virtual Conference 2021

View all of today’s events »

Today’s
Syndicate (7)

DRVN	IPO
KUKE	IPO
PLTK	IPO
AMWL	Secondary
ITP	Secondary
EAF	Spot Secondary
LTRN	Spot Secondary

View this week’s syndicate »

Get Full Fly Access

Breaking market intelligence sent straight to you: Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.

Up-to-date information on important industry events: Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.

News focused on the companies in your portfolio: Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.

14 Day Free Trial